Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Covetrus, Inc.

CVETNASDAQ
Healthcare
Medical - Distribution
$20.99
$0.00(0.00%)
U.S. Market opens in 15h 58m

Covetrus, Inc. Fundamental Analysis

Covetrus, Inc. (CVET) shows weak financial fundamentals with a PE ratio of -33.44, profit margin of -1.88%, and ROE of -5.64%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.33
Current Ratio1.94

Areas of Concern

ROE-5.64%
Operating Margin-0.48%
We analyze CVET's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 20.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
20.2/100

We analyze CVET's fundamental strength across five key dimensions:

Efficiency Score

Weak

CVET struggles to generate sufficient returns from assets.

ROA > 10%
-2.52%

Valuation Score

Excellent

CVET trades at attractive valuation levels.

PE < 25
-33.44
PEG Ratio < 2
-0.33

Growth Score

Weak

CVET faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

CVET maintains a strong and stable balance sheet.

Debt/Equity < 1
0.69
Current Ratio > 1
1.94

Profitability Score

Weak

CVET struggles to sustain strong margins.

ROE > 15%
-564.30%
Net Margin ≥ 15%
-1.88%
Positive Free Cash Flow
N/A

Key Financial Metrics

Is CVET Expensive or Cheap?

P/E Ratio

CVET trades at -33.44 times earnings. This suggests potential undervaluation.

-33.44

PEG Ratio

When adjusting for growth, CVET's PEG of -0.33 indicates potential undervaluation.

-0.33

Price to Book

The market values Covetrus, Inc. at 1.90 times its book value. This may indicate undervaluation.

1.90

EV/EBITDA

Enterprise value stands at -4.82 times EBITDA. This is generally considered low.

-4.82

How Well Does CVET Make Money?

Net Profit Margin

For every $100 in sales, Covetrus, Inc. keeps $-1.88 as profit after all expenses.

-1.88%

Operating Margin

Core operations generate -0.48 in profit for every $100 in revenue, before interest and taxes.

-0.48%

ROE

Management delivers $-5.64 in profit for every $100 of shareholder equity.

-5.64%

ROA

Covetrus, Inc. generates $-2.52 in profit for every $100 in assets, demonstrating efficient asset deployment.

-2.52%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $0.31 in free cash annually.

$0.31

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-33.44

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.33

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.90

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.69

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.94

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.06

vs 25 benchmark

ROA

Return on assets percentage

-0.03

vs 25 benchmark

ROCE

Return on capital employed

-0.01

vs 25 benchmark

How CVET Stacks Against Its Sector Peers

MetricCVET ValueSector AveragePerformance
P/E Ratio-33.4428.25 Better (Cheaper)
ROE-5.64%780.00% Weak
Net Margin-1.88%-20122.00% (disorted) Weak
Debt/Equity0.690.30 Weak (High Leverage)
Current Ratio1.944.66 Neutral
ROA-2.52%-14687.00% (disorted) Weak

CVET outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Covetrus, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ